Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT

NCT02877082 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT02877082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02877082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2016
Completion date
July 31, 2017
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, bcr-abl1 positive, diffuse large b-cell lymphoma, follicular lymphoma, graft versus host disease, mantle cell lymphoma, marginal zone lymphoma, myelodysplastic syndrome, myelofibrosis, myeloproliferative neoplasm, small lymphocytic lymphoma